CASI Stock Overview
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CASI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.43 |
| 52 Week High | US$8.48 |
| 52 Week Low | US$1.85 |
| Beta | 0.33 |
| 1 Month Change | -20.59% |
| 3 Month Change | -60.16% |
| 1 Year Change | -18.18% |
| 3 Year Change | -85.95% |
| 5 Year Change | -92.55% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?
Mar 16Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth
Feb 18
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?
Jan 23Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?
Dec 28CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer
Dec 23CASI Pharmaceuticals appoints Weihao Xu as CFO
Dec 16Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%
Dec 02The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares
Nov 27Casi Pharmaceuticals jumps 6% after CEO buys 227.5K shares
Nov 25Juventas initiates registration study for CNCT19
Nov 19CASI Pharmaceuticals EPS misses by $0.08, beats on revenue
Nov 09Shareholder Returns
| CASI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | -2.5% | -3.2% |
| 1Y | -18.2% | -3.7% | 19.3% |
Return vs Industry: CASI underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: CASI underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| CASI volatility | |
|---|---|
| CASI Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CASI's share price has been volatile over the past 3 months.
Volatility Over Time: CASI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 176 | Wei-Wu He | www.casipharmaceuticals.com |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc
CASI Pharmaceuticals, Inc. Fundamentals Summary
| CASI fundamental statistics | |
|---|---|
| Market cap | US$31.56m |
| Earnings (TTM) | -US$26.96m |
| Revenue (TTM) | US$33.88m |
0.9x
P/S Ratio-1.2x
P/E RatioIs CASI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CASI income statement (TTM) | |
|---|---|
| Revenue | US$33.88m |
| Cost of Revenue | US$13.83m |
| Gross Profit | US$20.05m |
| Other Expenses | US$47.01m |
| Earnings | -US$26.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 20, 2024
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 59.19% |
| Net Profit Margin | -79.58% |
| Debt/Equity Ratio | 78.2% |
How did CASI perform over the long term?
See historical performance and comparison